Samer Al Hadidi: Will use of CAR-T earlier be better?

Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:

“ASH23 multiple myeloma

KarMMa-3 updated analysis:
Despite improved PFS with earlier use of Ide-Cel, OS was not different Unfortunate we don’t have a tail for PFS with Ide-cel and unfortunate that OS is not better (per ITT, many pts died before product).

Will use of CAR-T earlier be better?“

Source: Samer Al Hadidi/X